Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Transcatheter mitral valve replacement after surgical repair or replacement : comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry. / Simonato, Matheus; Whisenant, Brian; Ribeiro, Henrique Barbosa; Webb, John G.; Kornowski, Ran; Guerrero, Mayra; Wijeysundera, Harindra; Søndergaard, Lars; de Backer, Ole; Villablanca, Pedro; Rihal, Charanjit; Eleid, Mackram; Kempfert, Jörg; Unbehaun, Axel; Erlebach, Magdalena; Casselman, Filip; Adam, Matti; Montorfano, Matteo; Ancona, Marco; Saia, Francesco; Ubben, Timm; Meincke, Felix; Napodano, Massimo; Codner, Pablo; Schofer, Joachim; Pelletier, Marc; Cheung, Anson; Shuvy, Mony; Palma, José Honório; Gaia, Diego Felipe; Duncan, Alison; Hildick-Smith, David; Veulemans, Verena; Sinning, Jan Malte; Arbel, Yaron; Testa, Luca; de Weger, Arend; Eltchaninoff, Helene; Hemery, Thibault; Landes, Uri; Tchetche, Didier; Dumonteil, Nicolas; Rodés-Cabau, Josep; Kim, Won Keun; Spargias, Konstantinos; Kourkoveli, Panagiota; Ben-Yehuda, Ori; Teles, Rui Campante; Barbanti, Marco; Fiorina, Claudia; Thukkani, Arun; Mackensen, G. Burkhard; Jones, Noah; Presbitero, Patrizia; Petronio, Anna Sonia; Allali, Abdelhakim; Champagnac, Didier; Bleiziffer, Sabine; Rudolph, Tanja; Iadanza, Alessandro; Salizzoni, Stefano; Agrifoglio, Marco; Nombela-Franco, Luis; Bonaros, Nikolaos; Kass, Malek; Bruschi, Giuseppe; Amabile, Nicolas; Chhatriwalla, Adnan; Messina, Antonio; Hirji, Sameer A.; Andreas, Martin; Welsh, Robert; Schoels, Wolfgang; Hellig, Farrel; Windecker, Stephan; Stortecky, Stefan; Maisano, Francesco; Stone, Gregg W.; Dvir, Danny.
I: Circulation, Bind 143, 49088, 2021, s. 104-116.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Transcatheter mitral valve replacement after surgical repair or replacement
T2 - comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry
AU - Simonato, Matheus
AU - Whisenant, Brian
AU - Ribeiro, Henrique Barbosa
AU - Webb, John G.
AU - Kornowski, Ran
AU - Guerrero, Mayra
AU - Wijeysundera, Harindra
AU - Søndergaard, Lars
AU - de Backer, Ole
AU - Villablanca, Pedro
AU - Rihal, Charanjit
AU - Eleid, Mackram
AU - Kempfert, Jörg
AU - Unbehaun, Axel
AU - Erlebach, Magdalena
AU - Casselman, Filip
AU - Adam, Matti
AU - Montorfano, Matteo
AU - Ancona, Marco
AU - Saia, Francesco
AU - Ubben, Timm
AU - Meincke, Felix
AU - Napodano, Massimo
AU - Codner, Pablo
AU - Schofer, Joachim
AU - Pelletier, Marc
AU - Cheung, Anson
AU - Shuvy, Mony
AU - Palma, José Honório
AU - Gaia, Diego Felipe
AU - Duncan, Alison
AU - Hildick-Smith, David
AU - Veulemans, Verena
AU - Sinning, Jan Malte
AU - Arbel, Yaron
AU - Testa, Luca
AU - de Weger, Arend
AU - Eltchaninoff, Helene
AU - Hemery, Thibault
AU - Landes, Uri
AU - Tchetche, Didier
AU - Dumonteil, Nicolas
AU - Rodés-Cabau, Josep
AU - Kim, Won Keun
AU - Spargias, Konstantinos
AU - Kourkoveli, Panagiota
AU - Ben-Yehuda, Ori
AU - Teles, Rui Campante
AU - Barbanti, Marco
AU - Fiorina, Claudia
AU - Thukkani, Arun
AU - Mackensen, G. Burkhard
AU - Jones, Noah
AU - Presbitero, Patrizia
AU - Petronio, Anna Sonia
AU - Allali, Abdelhakim
AU - Champagnac, Didier
AU - Bleiziffer, Sabine
AU - Rudolph, Tanja
AU - Iadanza, Alessandro
AU - Salizzoni, Stefano
AU - Agrifoglio, Marco
AU - Nombela-Franco, Luis
AU - Bonaros, Nikolaos
AU - Kass, Malek
AU - Bruschi, Giuseppe
AU - Amabile, Nicolas
AU - Chhatriwalla, Adnan
AU - Messina, Antonio
AU - Hirji, Sameer A.
AU - Andreas, Martin
AU - Welsh, Robert
AU - Schoels, Wolfgang
AU - Hellig, Farrel
AU - Windecker, Stephan
AU - Stortecky, Stefan
AU - Maisano, Francesco
AU - Stone, Gregg W.
AU - Dvir, Danny
N1 - Publisher Copyright: © 2020 American Heart Association, Inc.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. METHODS: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mmHg and significant residual mitral regurgitation (MR) as ≥ moderate. RESULTS: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mmHg (≥5 mmHg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient ≥5 mmHg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88-21.53; P<0.001) were both independently associated with repeat mitral valve replacement. CONCLUSIONS: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
AB - BACKGROUND: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. METHODS: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mmHg and significant residual mitral regurgitation (MR) as ≥ moderate. RESULTS: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mmHg (≥5 mmHg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient ≥5 mmHg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88-21.53; P<0.001) were both independently associated with repeat mitral valve replacement. CONCLUSIONS: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
KW - Heart valve disease
KW - Hemodynamics
KW - Mitral valve
KW - Mitral valve insufficiency
KW - Mitral valve stenosis
U2 - 10.1161/CIRCULATIONAHA.120.049088
DO - 10.1161/CIRCULATIONAHA.120.049088
M3 - Journal article
C2 - 32975133
AN - SCOPUS:85100069320
VL - 143
SP - 104
EP - 116
JO - Circulation
JF - Circulation
SN - 0009-7322
M1 - 49088
ER -
ID: 304054764